摘要
目的:探讨人附睾蛋白4(HE4)、抑制素A(inhibinA)及癌胚抗原125(CA125)在卵巢癌患者中的诊断价值。方法:应用ELISA法检测卵巢癌组、卵巢良性肿瘤组及正常对照组患者血清中HE4、InhibinA、CA125水平。结果:血清HE4水平:卵巢癌组(133.86±127.94)pmol/L、卵巢良性肿瘤组(42.67±22.77)pmol/L、正常对照组(33.40±19.50)pmol/L;血清InhibinA水平:卵巢癌组(177.22±114.35)ng/L、卵巢良性肿瘤组(76.60±14.10)ng/L、正常对照组(70.70±21.66)ng/L;血清CA125水平:卵巢癌组(750.52±1230.34)U/L、卵巢良性肿瘤组(67.25±106.16)U/L、正常对照组(17.69±6.13)U/L。统计学分析血清HE4、InhibinA数值显示:卵巢癌组与卵巢良性肿瘤组、正常对照组比较,P<0.05,差异有统计学意义;而卵巢良性肿瘤组与正常对照组比较,P>0.05,差异无统计学意义。血清CA125卵巢癌组与卵巢良性肿瘤组、正常对照组比较,P<0.05,差异有统计学意义;良性肿瘤组与正常对照组比较,P<0.05,差异有统计学意义。卵巢癌诊断中的阳性率分别是:HE4 71.8%、InhibinA 66.7%、CA125 61.5%,三者联合阳性率为92.3%。结论:HE4、InhibinA、CA125在卵巢癌诊断中有重要意义,三者联合检测能明显提高卵巢癌的诊断率。
Objective： To detect the level of serum human epididymis4,InhibinA and CA125 in patients with ovarian cancer.Methods： ELISA method was used to test serum HE4,InhibinA and CA125 in ovarian cancer group,benign ovarian tumor group and the healthy control.Results： The serum HE4 level of ovarian cancer group was（133.86 ± 127.94） pmol/L,benign ovarian tumor group was（42.67 ± 22.77） pmol / L,the healthy control was（33.40 ± 19.50） pmol / L;Serum InhibinA level： ovarian cancer group was（177.22 ± 114.35） ng / L,benign ovarian tumor group was（76.60 ±14.10） ng/L,the healthy control was（70.70 ±21.66） ng/L;Serum CA125 level： ovarian cancer group was（750.52 ± 1230.34） U / L,benign ovarian tumor group was（67.25 ± 106.16） U / L,the healthy control was（17.69 ±6.13） U/L.Serum HE4 and InhibinA： comparing with ovarian cancer group,ovarian benign tumor group and normal control group,P 0.05,and ovarian benign tumor group compared with normal control group,P 0.05.For CA125 comparing with ovarian cancer group,ovarian benign tumor group and normal control group,P ﹤ 0.05,the difference was statistically significant,benign tumor group compared with normal control group,P 0.05.The positive rate were： HE4 70.59%,InhibinA 66.7%,CA125 63.3%,the positive rate of combination was 93.3%.Conclusion： HE4,InhibinA,CA125 have important significance in the diagnosis of ovarian cancer,combination of these three markers can raise up the positive rate of diagnose of ovarian cancer.
出处
《现代肿瘤医学》
CAS
2012年第4期785-788,共4页
Journal of Modern Oncology
关键词
人附睾蛋白4
抑制素A
CA125
卵巢肿瘤
酶联免疫法
human epididymis protein 4
InhibinA
CA125
ovarian neopiasms
enzyme linked immunosorbent assay
